Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENSCIS-ON: Nintedanib Extension in SSc-ILD
NCT03313180Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2017
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 30
01
Overview
A Phase 3 trial of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by Boehringer Ingelheim. Started Nov 2017; status: completed.
02
Drugs
nintedanib
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT03313180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313180.